Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia

Current Medical Research and Opinion

Volumn 27, Issue 9, 2011, Pages 1793-1801

  Sun, Peter ^a   Zhao, Yang ^b   Zhao, Zhenxiang ^b   Watson, Peter ^b  

^a Kailo Research Group   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Dosing pattern; Duloxetine; Fibromyalgia; Pregabalin

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DULOXETINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREGABALIN; SEROTONIN ANTAGONIST;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG UTILIZATION; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ALGORITHMS; ANALGESICS; COMORBIDITY; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; THIOPHENES; YOUNG ADULT;

EID: 80051771019     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.605113     Document Type: Article

References (46)

1. Wolfe F, Hawley DJ, Goldenberg DL, et al. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. J Rheumatol 2000;27:1989-1999 (Pubitemid 30670493)
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172 (Pubitemid 20098653)
3. NIAMS. Fibromyalgia. 1999. Available at: http://www.niams.nih.gov/Health- Info/Fibromyalgia/default.asp [Last accessed 5 May 2009]
4. Topbas M, Cakirbay H, Gulec H, et al. The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand J Rheumatol 2005;34:140-144 (Pubitemid 40694834)
5. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006;12:124-128 (Pubitemid 44314970)
6. Toda K. The prevalence of fibromyalgia in Japanese workers. Scand J Rheumatol 2007;36:140-144 (Pubitemid 46685764)
7. Mas AJ, Carmona L, Valverde M, et al. Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: results from a nationwide study in Spain. Clin Exp Rheumatol 2008; 26:519-526
8. NFA. Prevalence of Fibromyalgia. 2009. Available at: http://www.fmaware. org/site/PageServeripagename¼fibromyalgia-affected [Last accessed 5 May 2009]
9. WD. Prevalence and Incidence of Fibromyalgia. Available at: http://www. wrongdiagnosis.com/f/fibromyalgia/stats.htm [Last accessed 5 May 2009]
10. Wolfe F, Petri M, Alarcon GS, et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol 2009; 36:82-8
11. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2009;39:448-453
12. Bannwarth B, Blotman F, Roue-Le Lay K, et al. Fibromyalgia syndrome in the general population of France: a prevalence study. Joint Bone Spine 2009; 76:184-187
13. Schochat T, Raspe H. Elements of fibromyalgia in an open population. Rheumatology (Oxford) 2003;42:829-835 (Pubitemid 37220930)
14. Bazelmans E, Vercoulen JH, Galama JM, et al. [Prevalence of chronic fatigue syndrome and primary fibromyalgia syndrome in The Netherlands]. Ned Tijdschr Geneeskd 1997;141:1520-1523 (Pubitemid 27317271)
15. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-1417 (Pubitemid 26258765)
16. Sardini S, Ghirardini M, Betelemme L, et al. [Epidemiological study of a primary fibromyalgia in pediatric age]. Minerva Pediatr 1996;48:543-550 (Pubitemid 127582187)
17. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28
18. Buskila D, Neumann L, Hershman E, et al. Fibromyalgia syndrome in children-an outcome study. J Rheumatol 1995;22:525-528
19. Al-Allaf AW. Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol 2007;13:199-201 (Pubitemid 47356787)
20. Robinson RL, Jones ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother 2006; 7:1027-1039 (Pubitemid 43949941)
21. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27
22. Shaver JL, Wilbur J, Robinson FP, et al. Women's health issues with fibromyalgia syndrome. J Womens Health (Larchmt) 2006;15:1035-1045 (Pubitemid 46389178)
23. Rutledge DN, Jones K, Jones CJ. Predicting high physical function in people with fibromyalgia. J Nurs Scholarsh 2007;39:319-324
24. Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508 (Pubitemid 47228612)
25. Panton LB, Kingsley JD, Toole T, et al. A comparison of physical functional performance and strength in women with fibromyalgia, age-and weightmatched controls, and older women who are healthy. Phys Ther 2006; 86:1479-1488 (Pubitemid 44672537)
26. Verbunt JA, Pernot DH, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes 2008;6:8
27. Kurtze N, Gundersen KT, Svebak S. Quality of life, functional disability and lifestyle among subgroups of fibromyalgia patients: the significance of anxiety and depression. Br J Med Psychol 1999;72(Pt 4):471-484 (Pubitemid 30018991)
28. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
29. Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome-a systematic review. Eur J Pain 2009;14:5-10
30. Sumpton JE, Moulin DE. Fibromyalgia: presentation and management with a focus on pharmacological treatment. Pain Res Manag 2008;13:477-483
31. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-541 (Pubitemid 351498437)
32. Guymer EK, Littlejohn GO. Fibromyalgia. Diagnosis and management. Australas Chiropr Osteopathy 2002;10:81-4
33. Garcia-Campayo J, Serrano-Blanco A, Rodero B, et al. Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. Trials 2009;10:24
34. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-444
35. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebocontrolled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15 (Pubitemid 41752960)
36. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-2984 (Pubitemid 39209537)
37. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2005;52:1264-1273 (Pubitemid 40530135)
38. Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, et al. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an openlabel, prospective trial. Pharmacopsychiatry 2007;40:68-71 (Pubitemid 46697677)
39. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, doubleblind, placebo-controlled trial with pregabalin. Pain 2008;136:419-431
40. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebocontrolled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-514 (Pubitemid 351374429)
41. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004
42. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-1985 (Pubitemid 41429029)
43. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19(Suppl 1):S27-35 (Pubitemid 39386317)
44. Zhao Y, Sun P, Watson P, et al. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract 2011;11:204-216
45. Lilly. Cymbalta Package Insert. 2004. Available at: http://pi.lilly.com/ us/cymbalta-pi.pdf [Last accessed 9 March 2011]
46. Pfizer. Lyrica Package Insert. 2004. Available at: http://dailymed.nlm. nih.gov/dailymed/drugInfo.cfm?id¼31444#nlmhighlights [Last accessed 9 March 2011]